Author:
Viana Veloso Gilson Gabriel,Amaral Flávia Duarte,Nogueira-Rodrigues Angélica
Abstract
Abstract
Background
There is no updated national data regarding the real impact of the COVID-19 pandemic on delaying diagnosis and treatment among patients with lung, and head, and neck cancers in Brazil. This study aimed to analyze the COVID-19 pandemic impact on cancer diagnosis and clinical outcomes among lung, head, and neck cancer patients assisted in a tertiary cancer center in Southeastern Brazil, as well as to analyze these patients’ pretreatment clinical features.
Methods
Retrospective cohort of patients with lung or head and neck cancer assisted in a tertiary cancer center in southeastern Brazil between January/2019 and December/2021. To assess statistical differences among groups [i.e., cohort 2019 versus (vs.) 2020 and 2019 vs. 2021] chi-square test was used with a 5% significance level and 90% power for sample size calculation. Differences among baseline clinical features and sociodemographic characteristics were evaluated either by T-test for two samples or Fisher’s or Pearson’s chi-square test (for quantitative or qualitative variables). All utilized tests had a 5% significance level.
Results
Six hundred fifty-two patients were included, 332 with lung and 320 with head and neck cancer; it was observed a significant decrease in oncologic treatment recommendations and increase in palliative care recommendation for patients with lung cancer, despite similar stages at diagnosis. During the COVID-19 pandemic, more pain symptoms were reported at the first Oncology assessment for patients with head and neck cancer (p < 0.05). Compared to 2019, head and neck cancer patients diagnosed in 2021 presented a worse initial performance status (p = 0.008). There was a statistically significant increase in survival for patients diagnosed with head and neck cancer in 2021 when compared to 2019 (p = 0.003).
Conclusions
This research highlights low survival rates for patients with lung and head and neck cancer in Brazil, even before the pandemic started, as consequence of advanced diseases at diagnosis at the public health system and clinical degrading features. Additionally, there was an increase incidence in both lung cancer and head and neck cancer despite no differences in clinical stage. This reflects how fragile is the public healthcare system even before facing an acute public health crisis such as the COVID-19 pandemic. Yet, the total impact on public health may follow for many years.
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. World Health Organization. Cancer. Available at: https://www.who.int/health-topics/cancer#tab=tab_1. Access 1 Feb 2023
2. World Health Organization. IAEA/WHO Joint Statement on Reducing Inequity in Access to Cancer Care through Rays of Hope Initiative. Available at: https://www.who.int/news/item/04-02-2022-iaea-who-joint-statement-on-reducing-inequity-in-access-to-cancer-care-through-rays-of-hope-initiative#:~:text=World%20Health%20Organization,expected%20to%20occur%20in%20LMICs. Access 1 Feb 2023.
3. Brasil. Instituto Nacional De Câncer (Brasil). Estimativa 2023: incidência de câncer no Brasil / Instituto Nacional De Câncer. – Rio de Janeiro: INCA; 2022. 160 p.: il. color.
4. World Health Organization. Coronavirus disease (COVID-19). Available at: https://covid19.who.int/. Access 1 Feb 2023.
5. Shah MA, Mayer S, Emlen F, et al. Clinical screening for COVID-19 in asymptomatic patients with Cancer. JAMA Netw Open. 2020;3(9):e2023121. https://doi.org/10.1001/jamanetworkopen.2020.23121.